Solórzano-Santos F, Miranda-Novales MG

Idioma: Español
Referencias bibliográficas: 31
Paginas: 461-473
Archivo PDF: 194.05 Kb.

RESUMEN

La influenza es una infección viral aguda de las vías respiratorias, altamente contagiosa. Es causada por el virus de la influenza A, B y C. Puede afectar a todos los grupos etarios durante epidemias, aunque tiene mayor morbilidad en los extremos de la vida. La enfermedad frecuentemente requiere de atención médica y hospitalización, contribuyendo sustancialmente a pérdidas económicas, exceso en el número de días/cama-hospital y muertes. Considerando la epidemia reciente en México del virus de la influenza humana H1N1, y la presencia de brotes epidémicos estacionales, se presenta esta actualización, haciendo énfasis en los aspectos de prevención y tratamiento.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Cox NJ, Subbarao K. Influenza. Lancet. 1999; 354: 1277-82.

2. Osterholm MT. Preparing for the next pandemic. N Engl J Med. 2005; 352: 1839-41.

3. Forsberg-White L, Pagano M. Transmissibility of the influenza virus in the 1918 pandemic. Available from: PLoS ONE 3(1): e1498. doi:10.1371/journal.pone.0001498.

4. CDC. Update: Influenza activity - United States, 2003-2004 Season. MMWR Morb Mortal Wkly Rep. 2004; 52: 1197-202.

5. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006; 12:.9-14.

6. Kilbourne ED. Influenza pandemics: can we prepare for the unpredictable? Viral Immunol. 2004; 17: 350-7.

7. Kuri-Morales P, Galván F, Cravioto P, Zárraga-Rosas LA, Tapia-Conyer R. Mortalidad en México por influenza y neumonía (1990-2005). Salud Publica Mex. 2006; 48: 379-84.

8. Trifonov V, Khiabanian H, Rabadan P. Geographic dependence, surveillance, and origins of the 2009 influenza A (H1N1) virus. N Engl J Med. Available from: 10.1056/nejmp0904572.

9. http://www.cdc.gov/flu/weekly/fluactivity.htm

10. CDC. Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58: 400-2.

11. CDC. Outbreak of swine-origin influenza A (H1N1) virus infection-Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58: 467-70.

12. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Kerkhove M, Hollingsworth TD, et al., and the WHO Pandemic Assessment Collaboration. Pandemic potential of a strain of influenza A (H1N1): Early findings. Available from: www.sciencexpress.org/11May2009/10.1126/science.1176062

13. Dirección General de Epidemiología: Anuarios de Morbilidad. Disponible en: http://www.dgepi.com.mx. Acceso: Junio 4, 2009.

14. General Directorate of Epidemiology, Ministry of Health, Mexico; Pan American Health Organization; World Health Organization; Public Health Agency of Canada; Influenza Div., National Center for Immunization and Respiratory Diseases, CDC Influenza Emergency Response Team. Update: Novel Influenza A (H1N1) Virus Infections - Worldwide, May 6, 2009. May 8, 2009/Vol. 58/No. 17.

15. Patrozou E, Mermel L. Does influenza transmission occur from asymptomatic infection or prior to symptom onset? Public Health Rep. 2009; 124: 193-6.

16. Bhat N, Wright JG, Broder KR. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005; 353: 2559-67.

17. CDC. H1N1 Flu (Swine Flu). Available from: http://www.cdc.gov/h1n1flu/

18. Rothberg RB, Haessler SD, Brown RB. Complications of viral influenza. Am J Med. 2008; 121: 258-64.

19. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, et al. Seasonal influenza in adults and children - Diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: Clinical Practice Guidelines of the Infectious Diseases Society of America. CID. 2009; 48: 1003-32.

20. CDC. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunizations Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2008-2009.

21. MacIntyre CR, Cauchemez S, Dwyer DE, Seale H, Cheung P, Browne G, et al. Face -mask use and control of respiratory virus transmission in households. Emerg Infect Dis. 2009; 15: 233-41.

22. Hayden FG. Antivirals for influenza: Historical perspectives and lessons learned. Antiviral Res. 2006; 71: 372-8.

23. Shiraishi K, Mitamur K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis. 2003; 188: 57-61.

24. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006; 367: 303-13.

25. CDC. Antiviral agents for influenza: Background information for clinicians. Available from: http://www.cdc.gov/flu/professionals/antiviralback.htm

26. Kawai N, Ikematsu H, Iwaki N, Maeda T, Kanazawa H, Kawashima T, et al. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. J Infect. 2008; 56: 51-7.

27. Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami Ch, Kawaoka Y, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. CID. 2008; 47: 339-45.

28. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006; 50: 2395-402.

29. Escuret V, Frobert E, Buscambert-Duchamp M, Sabatier M, Grog I, Valette M, et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol. 2008; 41: 25-8.

30. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine. 2000; 18: 957-1030.

31. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis. 2008; 8: 571-6.